Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/11/2019 02/12/2019 02/13/2019 02/14/2019 02/15/2019 Date
76.71(c) 78.52(c) 79.02(c) 78.94(c) 79.81(c) Last
13 171 650 13 049 725 10 477 211 8 184 201 10 350 166 Volume
-1.04% +2.36% +0.64% -0.10% +1.10% Change
More quotes
Financials (USD)
Sales 2019 44 425 M
EBIT 2019 14 889 M
Net income 2019 10 391 M
Debt 2019 14 420 M
Yield 2019 2,78%
Sales 2020 46 758 M
EBIT 2020 16 321 M
Net income 2020 -
Debt 2020 12 702 M
Yield 2020 2,82%
P/E ratio 2019 19,86
P/E ratio 2020 17,20
EV / Sales2019 5,00x
EV / Sales2020 4,71x
Capitalization 208 B
More Financials
Company
Merck and Company specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (72.8%): for treating hypertension, osteoporosis, atherosclerosis, respiratory,... 
Sector
Pharmaceuticals
Calendar
02/16 | 05:00pmPresentation
More about the company
Surperformance© ratings of Merck and Company
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK AND COMPANY
02/16MERCK AND : KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Red..
BU
02/16MERCK AND : Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncolo..
AQ
02/15MERCK AND : Gets FDA Priority Review for Keytruda/Inlyta Combo in Kidney Cancer
DJ
02/15MERCK AND : FDA Grants Priority Review to Merck's Supplemental Biologics License..
BU
02/15MERCK AND : Cerecor Announces CERC-301 Granted U.S. Patent
AQ
02/15MERCK : Pfizer up the pressure on BMS in first-line kidney cancer
AQ
02/14MERCK AND : Statement of Changes in Beneficial Ownership
PU
02/14MERCK : Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology P..
BU
02/13MERCK AND : Mercks Keytruda gets boost in kidney and head and neck cancer
AQ
02/13MERCK AND : SELLAS Life Sciences Provides Galinpepimut-S and Nelipepimut-S Progr..
AQ
More news
Analyst Recommendations on MERCK AND COMPANY
More recommendations
Sector news : Pharmaceuticals - NEC
06:05pCash-hoarding Japanese firms please investors as share buybacks hit record
RE
02/15BRISTOL MYERS SQUIBB : Starboard gauges Bristol-Myers shareholder support for Ce..
RE
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/15WSJ TAX GUIDE 2019 : What Investors Need to Know -2-
DJ
02/15WSJ TAX GUIDE 2019 : What Investors Need to Know -- Journal Report
DJ
More sector news : Pharmaceuticals - NEC
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 82,5 $
Spread / Average Target 3,4%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY4.45%207 536
JOHNSON & JOHNSON4.08%365 768
PFIZER-3.85%245 920
ROCHE HOLDING LTD.11.98%233 242
NOVARTIS7.19%228 685
ELI LILLY AND COMPANY4.35%129 746